Trillium Therapeutics Inc (NASDAQ:TRIL) (TSE:TR) has earned a consensus recommendation of “Buy” from the six research firms that are covering the company, MarketBeat reports. Three research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $10.00.
Several analysts have issued reports on the stock. JMP Securities initiated coverage on shares of Trillium Therapeutics in a research note on Tuesday, May 26th. They issued an “outperform” rating and a $10.00 price objective for the company. BidaskClub raised shares of Trillium Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Zacks Investment Research downgraded shares of Trillium Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, May 21st. Finally, ValuEngine raised shares of Trillium Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, April 2nd.
Large investors have recently modified their holdings of the stock. Marshall Wace LLP acquired a new position in shares of Trillium Therapeutics in the 1st quarter valued at $73,000. Jane Street Group LLC acquired a new position in shares of Trillium Therapeutics in the 4th quarter valued at $29,000. FNY Investment Advisers LLC acquired a new position in shares of Trillium Therapeutics in the 1st quarter valued at $343,000. Lindbrook Capital LLC acquired a new position in shares of Trillium Therapeutics in the 1st quarter valued at $40,000. Finally, Coastal Investment Advisors Inc. lifted its stake in shares of Trillium Therapeutics by 144.3% in the 1st quarter. Coastal Investment Advisors Inc. now owns 42,750 shares of the biotechnology company’s stock valued at $173,000 after purchasing an additional 25,250 shares during the last quarter. 73.51% of the stock is owned by institutional investors.
Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) last announced its quarterly earnings data on Friday, May 15th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.09) by ($0.14). As a group, equities research analysts expect that Trillium Therapeutics will post -0.69 EPS for the current year.
About Trillium Therapeutics
Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company's lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trials for advanced hematologic malignancies, and solid tumors and mycosis fungoides.
Featured Article: Trading Ex-Dividend Strategy
Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.